Gilead: Q4 EPS plunge 75% to $0.3
Gilead Sciences Inc. said on Tuesday that its diluted earnings per share (EPS) stood at $0.3 in the final quarter of fiscal 2021, marking a 75% drop from the same period a year ago. The drop was attributed to a $1.25 billion charge in a legal settlement. The full-year figure flew from $0.1 to $4.93 on an annual comparison basis.
The company’s total revenues yearly declined by 2.38% to $7.24 billion in the trimester, while the full-year revenues expanded by 10.6% compared to 2020 to reach $27.3 billion. Net income amounted to $382 million in the final three-month period of the year, and to $6.2 billion in the entire 2021.
“Gilead is at an important point in its transformation journey, having built considerable momentum in the expansion of our commercial and clinical portfolios in both virology and oncology in 2021,” CEO Daniel O’Day said.
The company’s shares dived over 3.5% in the after-hours trade after the release.
Get involved!
Comments